/ Anktiva

ImmunityBio Surges as Anktiva Drives 671% Revenue Growth
/ Market Analysis

ImmunityBio Surges as Anktiva Drives 671% Revenue Growth

IBRX extended its rally after the company posted explosive 671% revenue growth, fueled by rising demand for its bladder cancer drug, Anktiva.

February 25, 2026
Why Is ImmunityBio (IBRX) Rallying Today? EU Approves Anktiva

Why Is ImmunityBio (IBRX) Rallying Today? EU Approves Anktiva

ImmunityBio stock surged more than 20% after the European Commission granted conditional approval for its bladder cancer treatment, Anktiva.

February 18, 2026
Amid Biotech Pitfalls, this Stock Has Outperformed NVDA in the Last 3 Months

Amid Biotech Pitfalls, this Stock Has Outperformed NVDA in the Last 3 Months

In the last three months, this biotech stock outperformed Nvidia (NVDA) by over 3x.

May 13, 2024

Trending

BioNTech (BNTX) Stock Plunges 20% After Earnings Miss and Leadership Change
BioNTech (BNTX) Stock Plunges 20% After Earnings Miss and Leadership Change
March 10, 2026
NVDA Stock Moves Higher After AI Infrastructure Deal With Thinking Machines Lab
NVDA Stock Moves Higher After AI Infrastructure Deal With Thinking Machines Lab
March 10, 2026
Why Did MiNK Therapeutics (INKT) Stock Jump 50% Premarket Today?
Why Did MiNK Therapeutics (INKT) Stock Jump 50% Premarket Today?
March 10, 2026
Earnings Recap: ABM, UNFI, and Kohl’s Report Mixed Quarterly Results
Earnings Recap: ABM, UNFI, and Kohl’s Report Mixed Quarterly Results
March 10, 2026